Presbyopia – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Presbyopia – Drugs In Development, 2024 report and make more profitable business decisions.
Presbyopia is an eye condition in which the eyes slowly lose the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eye strain, difficulty reading small print, and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis, and eye trauma.
The Presbyopia drugs in development market research report provide comprehensive information on the therapeutics under development for Presbyopia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Presbyopia and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Presbyopia | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 26 molecules, with 26 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Presbyopia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Presbyopia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Presbyopia treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Arctic Vision Shanghai Biotechnology Co LtdCellix Bio Pvt Ltd
Cloudbreak Therapeutics LLC
Eyenovia Inc
Glaukos Corp
KSbitugen Co Ltd
Kubota Vision Inc
LentoBio Inc
Lenz Therapeutics LLC
Novartis AG
Ocuphire Pharma Inc
Plex Pharmaceuticals Inc
Santen Pharmaceutical Co Ltd
Seinda Pharmaceutical Guangzhou Corp
Suzhou Pro-Heal Pharmaceutical Technology Co Ltd
TelomEye Pharmaceuticals Corp
Theratocular Biotek Co Ltd
Viatris Inc
Visus Therapeutics Inc
Vyluma Inc
Zhaoke Ophthalmology Ltd
Zhejiang Raytone Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Presbyopia reports